2B78:F:F-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.674

Change

-0.02 (-0.27)%

Market Cap

N/A

Volume

99.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.09 (+0.31%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.17 (+0.32%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

-3.62 (-0.59%)

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+1.05 (+1.85%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.04 (+0.23%)

USD 63.18B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.21 (-0.19%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+1.47 (+1.35%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.70 (+1.12%)

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

+0.06 (+0.73%)

USD 43.12B
0ZC:F Zscaler Inc

+1.30 (+0.67%)

USD 37.92B

ETFs Containing 2B78:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.18% 78% C+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.18% 78% C+ 66% D+
Trailing 12 Months  
Capital Gain 12.94% 61% D- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.94% 56% F 52% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.02% 13% F 29% F
Dividend Return -5.02% 11% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.61% 54% F 85% B
Risk Adjusted Return -39.85% 18% F 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.